Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

Inclusion Criteria:

- Women between 35 and 50 years of age (inclusive)

- Women who will be scheduled to undergo an RRSO or RRs

- Women who will have at least one fallopian tube removed for risk-reducing reasons
(with or without removal of ovar(ies))

- Women who are willing to have a Mirena® IUD inserted at least prior to risk-reducing
surgery or who already have the Mirena® in place

- Women using non-hormonal forms of contraception (Note: If a copper IUD is being used,
the IUD must be removed prior to or at time of Mirena insertion.)

Exclusion Criteria:

- Any medical contraindication to use of a Mirena® IUD, including:

- Pregnancy (a pregnancy test is required prior to study entry)

- Known uterine anomaly that distorts the shape of the uterine cavity

- Acute pelvic inflammatory disease

- Postpartum endometritis or endometrial infection

- Known or suspected uterine or cervical neoplasia

- Known history or suspected breast cancer or other progestin-sensitive cancer

- Uterine bleeding of unknown etiology.

- Untreated acute cervicitis, vaginitis, or other lower genital tract infections

- Acute liver disease or liver tumor (benign or malignant)

- Use of tamoxifen, raloxifene, or chemotherapy within the previous 6 months

- Positive pregnancy test

- Breastfeeding

- Use of a copper IUD if the patient is not willing to have it removed prior to surgery
and replaced with a Mirena® IUD